123i-altropane
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2010 (NCT00724906)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 123-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- 123i-altropane
- 123i-altropane
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05636852 | Phase 2 | Feb 13, 2023 | General Electric, LabCorp |
| NCT00724906 | Phase 3 | Jul 1, 2010 | Alseres Pharmaceuticals, Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alseres Pharmaceuticals, Inc | For profit | 1 | 1 | 1 | 2010 |
| General Electric | For profit | 1 | 1 | 1 | 2023 |
| LabCorp | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1